(Reuters) – Catalent head of state and chief government officer Alessandro Maselli said on Monday he will definitely stay on because the settlement drugmaker’s principal after it’s gotten by Novo Holdings, the managing investor of weight-loss medication provider Novo Nordisk.
Maselli’s open letter begins the rear of objection over Novo Holding’s buy of Catalent, which united state buyer groups suppose can endanger rivals in weight-loss medicines and complicated genetics therapies.
Catalent will definitely run as an unbiased settlement drugmaker additionally after the acquisition, Maselli said, together with that he meant to “correct a few key inaccuracies that have been reported” concerning the acquisition.
Several united state buyer groups and a pair of huge organized labor lately prompted the united state Federal Trade Commission to impede the $16.5 billion provide, which Novo Holdings has truly said would definitely enhance provide of Wegovy, Novo’s smash hit GLP-1 injectable weight-loss medication.
(Reporting by Leroy Leo in Bengaluru; Editing by Shinjini Ganguli)
